Biologics for Atopic Dermatitis
- PMID: 33012322
- DOI: 10.1016/j.iac.2020.06.004
Biologics for Atopic Dermatitis
Abstract
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that has become a global health problem. The pathophysiology of AD includes both skin barrier and immune abnormalities, with type 2 immune deviation central to several clinical phenotypes and underlying endotypes. Recognition of the persistent nature and systemic aspects of AD provides a rationale for treatment with a biologic. Dupilumab has been approved for patients 6 years of age and older with moderate to severe AD. Monoclonal antibodies are in phase 3 trials and may become part of a precision medicine approach to AD.
Keywords: Atopic dermatitis; Biologics; Dupilumab; Immune dysregulation; Lebrikizumab; Nemolizumab; Omalizumab; Tralokinumab.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest M. Boguniewicz has served as a consultant for Regeneron and Sanofi-Genzyme.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
